Skip to main content
Home > Week in Review > Sales & Marketing

Chronological Index of : Sales and Marketing

 Current Issue
  • Dendreon sales and marketing update

    Dendreon Corp. (Pink:DNDNQ), Seattle, Wash. Business: Cancer On March 19, Germans Institute for Quality and Efficiency in Health Care (IQWiG) said in an addendum to a January early benefit assessment that Provenge …

    Published on 4/27/2015
  • Medivation, Astellas sales and marketing update

    Medivation Inc. (NASDAQ:MDVN), San Francisco, Calif. Astellas Pharma Inc. (Tokyo:4503), Tokyo, Japan Business: Cancer Germanys Institute for Quality and Efficiency in Healthcare (IQWiG) said in an assessment that Xtandi…

    Published on 4/27/2015
  • Novo Nordisk sales and marketing update

    Novo Nordisk A/S (CSE:NVO; NYSE:NVO), Bagsvaerd, Denmark Business: Endocrine/Metabolic Novo Nordisk launched Saxenda liraglutide in the U.S. for weight management as an adjunct to diet and exercise in adults with a BMI …

    Published on 4/27/2015
  • Thermo Fisher sales and marketing update

    Thermo Fisher Scientific Inc. (NYSE:TMO), Waltham, Mass. Business: Cancer Thermo Fisher launched its CE-IVD Oncomine Solid Tumour Fusion Transcript Kit in the EU to sequence formalin-fixed, paraffin-embedded (FFPE) …

    Published on 4/27/2015
  • uniQure, Chiesi sales and marketing update

    uniQure N.V. (NASDAQ:QURE), Amsterdam, the Netherlands Chiesi Farmaceutici S.p.A., Parma, Italy Business: Endocrine/Metabolic Germanys Federal Joint Committee (G-BA) suspended assessment of Glybera alipogene tiparvovec …

    Published on 4/27/2015
  • CombiMatrix, InterWest Health LLC sales and marketing update

    CombiMatrix Corp. (NASDAQ:CBMX), Irvine, Calif. InterWest Health LLC, Missoula, Mont. Business: Diagnostic InterWest will cover CombiMatrixs diagnostic laboratory services. InterWest has over 25,000 hospitals, …

    Published on 4/20/2015
  • Critical Diagnostics sales and marketing update

    Critical Diagnostics, San Diego, Calif. Business: Diagnostic Critical Diagnostics launched its Aspect-PLUS ST2 lateral flow immunoassay in the EU and the Asia-Pacific region. The assay measures the level of IL-1 …

    Published on 4/20/2015
  • Recombine Inc., Sequenom sales and marketing update

    Recombine Inc., New York, N.Y. Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Business: Diagnostic Sequenom and Recombine launched Sequenoms HerediT Universal genetic screening test in the U.S. The test screens for more…

    Published on 4/20/2015
  • Cancer Genetics sales and marketing update

    Cancer Genetics Inc. (NASDAQ:CGIX), Rutherford, N.J. Business: Diagnostic Cancer Genetics said Americas Choice Provider Network, a national network of healthcare providers, will cover CGIs cancer diagnostic services. …

    Published on 4/13/2015
  • Endo sales and marketing update

    Endo International plc (NASDAQ:ENDP; TSX:ENL), Dublin, Ireland Business: Endocrine/Metabolic Endo launched testosterone replacement therapy Natesto testosterone nasal gel in the U.S. Natesto is a bioadhesive intranasal …

    Published on 4/13/2015
  • Exact Sciences, Tufts Health Plan sales and marketing update

    Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Tufts Health Plan, Watertown, Mass. Business: Cancer Tufts will cover Exacts Cologuard to screen for colon cancer. The test is available to members ages 50 and older who…

    Published on 4/13/2015
  • Merck sales and marketing update

    Merck & Co. Inc. (NYSE:MRK), Whitehouse Station, N.J. Business: Infectious Merck launched Gardasil 9 in Canada to prevent cancers caused by HPV types 6, 11, 16, 18, 31, 33, 45, 52 and 58 in females ages 9-45 and males …

    Published on 4/13/2015
  • Omeros sales and marketing update

    Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Business: Ophthalmic Omeros launched Omidria in the U.S. to maintain intraoperative mydriasis (pupil size) by preventing intraoperative miosis and to reduce postoperative …

    Published on 4/13/2015
  • Aetna, U.S. Department of Health and Human Services sales and marketing update

    Aetna Inc. (NYSE:AET), Hartford, Conn. U.S. Department of Health and Human Services, Washington, D.C. Business: Infectious Aetna said its CoventryOne unit will move most of the HIV drugs in its Florida formulary from …

    Published on 4/6/2015
  • Agena Bioscience sales and marketing update

    Agena Bioscience Inc., San Diego, Calif. Business: Pharmacogenetics Agena launched the research use-only LungFUSION panel worldwide to identify anaplastic lymphoma kinase (ALK), ret proto-oncogene (RET) and c-ros proto-…

    Published on 4/6/2015
  • Dendreon sales and marketing update

    Dendreon Corp. (Pink:DNDNQ), Seattle, Wash. Business: Cancer The U.K.s NICE issued final guidance recommending against the use of Dendreons Provenge sipuleucel-T to treat asymptomatic or minimally symptomatic metastatic…

    Published on 4/6/2015
  • Hospira sales and marketing update

    Hospira Inc. (NYSE:HSP), Lake Forest, Ill. Business: Autoimmune, Biosimilars Hospira launched Inflectra infliximab in Canada to treat rheumatoid arthritis (RA), psoriatic arthritis, ankylosing spondylitis and plaque …

    Published on 4/6/2015
  • Sanofi sales and marketing update

    Sanofi (Euronext:SAN; NYSE:SNY), Paris, France Business: Endocrine/Metabolic Sanofi launched once-daily Toujeo insulin glargine in the U.S. to improve glycemic control in Type I and II diabetics. The product is a 300 …

    Published on 4/6/2015
  • Shire sales and marketing update

    Shire plc (LSE:SHP; NASDAQ:SHPG), Dublin, Ireland Business: Endocrine/Metabolic Shire launched Natpara in the U.S. as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. The …

    Published on 4/6/2015
  • Alfa Wassermann, Norgine sales and marketing update

    Alfa Wassermann S.p.A., Bologna, Italy Norgine B.V., Amsterdam, the Netherlands Business: Hepatic The U.K.s NICE issued final guidance recommending 550 mg Targaxan rifaximin from Norgine to prevent recurrence of …

    Published on 3/30/2015
  • Bayer A sales and marketing update

    Bayer AG (Xetra:BAYN), Leverkusen, Germany Business: Cardiovascular The U.K.s NICE issued final guidance recommending use of Xarelto rivaroxaban from Bayer in combination with aspirin plus clopidogrel or aspirin alone …

    Published on 3/30/2015
  • Boehringer Ingelheim, Eli Lilly sales and marketing update

    Boehringer Ingelheim GmbH, Ingelheim, Germany Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Endocrine/Metabolic The U.K.s NICE issued final guidance recommending Jardiance empagliflozin from Boehringer …

    Published on 3/30/2015
  • Celgene Corp sales and marketing update

    Celgene Corp. (NASDAQ:CELG), Summit, N.J. Business: Cancer The U.K.s NICE issued final guidance recommending against use of Imnovid pomalidomide from Celgene in combination with dexamethasone to treat relapsed and …

    Published on 3/30/2015
  • Eisai sales and marketing update

    Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Eisais Eisai Inc. subsidiary launched Lenvima lenvatinib in the U.S. to treat progressive, differentiated thyroid cancer in patients whose disease progressed …

    Published on 3/23/2015
  • Exact Sciences, Aetna sales and marketing update

    Exact Sciences Corp. (NASDAQ:EXAS), Madison, Wis. Aetna Inc. (NYSE:AET), Hartford, Conn. Business: Cancer Aetna will cover Exacts Cologuard to diagnose colon cancer, effective for three years starting April 1. Cologuard…

    Published on 3/23/2015

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993